Core Viewpoint - Silver诺医药-B (02591) experienced a decline of over 13% after a significant increase of 50% in the previous two weeks [1] Group 1: Stock Performance - As of the report, the stock price dropped by 13.64%, trading at 38 HKD with a transaction volume of 30.31 million HKD [1] Group 2: Regulatory Changes - The Shanghai and Shenzhen Stock Exchanges announced adjustments to the Hang Seng Composite MidCap Index, resulting in Silver诺医药 being included in the Hong Kong Stock Connect list, effective from December 8, 2025 [1] Group 3: Product Development - Silver诺医药's self-developed long-acting GLP-1 receptor agonist, Eysuparaglutide α (怡诺轻®), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented alongside the new list starting January 1, 2026 [1]
港股异动 | 银诺医药-B(02591)回吐逾13% 此前两周累计涨幅达50% 今日起正式进入港股通